The therapeutic landscape of chronic myeloid leukemia (CML) has profoundly changed over
the past 7 years. Most patients with chronic phase (CP) now have a normal life expectancy …

FGFRs are receptor tyrosine kinases with a role in several biological processes, such as the
regulation of development and tissue repair. However, alterations in FGFRs 1–4, such as …

The sites of targeted therapy are limited and need to be expanded. The FGF‐FGFR
signalling plays pivotal roles in the oncogenic process, and FGF/FGFR inhibitors are a …

This analysis from the multicenter, open-label, phase 3 BFORE trial reports efficacy and
safety of bosutinib in patients with newly diagnosed chronic phase (CP) chronic myeloid …

The CRISPR/Cas9 system is an RNA-based adaptive immune system in bacteria and
archaea. Various studies have shown that it is possible to target a wide range of human …

In recent years, the lymphocyte-specific protein tyrosine kinase (Lck) has emerged as one of
the key molecules regulating T-cell functions. Studies using Lck knock-out mice or Lck …

Tyrosine kinase inhibitors (TKIs), the treatment of choice for chronic myeloid leukemia
(CML), can be associated to cardiovascular (CV) adverse events (AEs). A case/non-case …

The selection of cancer medicines for national procurement requires deliberate evaluation of
population benefit, budget impact, sustainability, and health system capacity. However, this …

Cancer cells produce elevated levels of reactive oxygen species, which has been used to
design cancer specific prodrugs. Their activation relies on at least a bimolecular process, in …

Hematological malignancies (HM) are a collection of malignant transformations originating
from cells in the primary or secondary lymphoid organs. Leukemia, lymphoma, and multiple …